- Home
- PEW vs MAIA Comparison
PEW vs MAIA Comparison
Compare PEW & MAIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
Current Price
$3.07
HOLD
Current Price
$1.49
Company Overview
Basic Information| Metric | PEW | MAIA |
|---|---|---|
| Founded | 2007 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 84.9M | 89.7M |
| IPO Year | N/A | 2022 |
Fundamental Metrics
Financial Performance| Metric | PEW | MAIA |
|---|---|---|
| Price | $3.07 | $1.49 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $6.75 | N/A |
| AVG Volume (30 Days) | 497.2K | ★ 1.2M |
| Earning Date | 03-12-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 29.53 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $1.89 | N/A |
| Revenue Next Year | $8.43 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.55 | $0.87 |
| 52 Week High | $10.04 | $3.19 |
Technical Indicators
Market Signals| Indicator | PEW | MAIA |
|---|---|---|
| Relative Strength Index (RSI) | 55.48 | 38.07 |
| Support Level | $2.74 | $1.44 |
| Resistance Level | $3.29 | $1.74 |
| Average True Range (ATR) | 0.14 | 0.09 |
| MACD | 0.03 | -0.01 |
| Stochastic Oscillator | 57.55 | 48.19 |
Price Performance
Historical Comparison PEW
MAIA
About PEW GrabAGun Digital Holdings Inc.
GrabAGun Digital Holdings Inc is a multi-brand eCommerce retailer of firearms, ammunition, and related accessories.
About MAIA MAIA Biotechnology Inc.
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. THIO (6-thio-dG or 6-thio-2 '-deoxyguanosine), its lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. Patients with advanced NSCLC will be treated first with THIO followed a few days later by the immune checkpoint inhibitor Libtayo (cemiplimab), manufactured and commercialized by Regeneron.